title: Antenatal magnesium individual participant data international collaboration: assessing the benefits for babies using the best level of evidence (AMICABLE).
abstract: BACKGROUND
  The primary aim of this study is to assess, using individual participant data (IPD) meta-analysis, the effects of administration of antenatal magnesium sulphate given to women at risk of preterm birth on important clinical outcomes for their child such as death and neurosensory disability. The secondary aim is to determine whether treatment effects differ depending on important pre-specified participant and treatment characteristics, such as reasons at risk of preterm birth, gestational age, or type, dose and mode of administration of magnesium sulphate.
  
  
  METHODS
  
  
  
  METHODS
  The Antenatal Magnesium Individual Participant Data (IPD) International Collaboration: assessing the benefits for babies using the best level of evidence (AMICABLE) Group will perform an IPD meta-analysis to answer these important clinical questions. SETTING/TIMELINE: The AMICABLE Group was formed in 2009 with data collection commencing late 2010.
  
  
  METHODS
  Five trials involving a total 6,145 babies are eligible for inclusion in the IPD meta-analysis. PRIMARY STUDY OUTCOMES: For the infants/children: Death or cerebral palsy. For the women: Any severe maternal outcome potentially related to treatment (death, respiratory arrest or cardiac arrest).
  
  
  CONCLUSIONS
  Results are expected to be publicly available in 2012.
authors.affiliation: Australian Research Centre for Health of Women and Babies (ARCH), Discipline of Obstetrics and Gynaecology, Women's and Children's Hospital, The University of Adelaide, Adelaide, Australia. caroline.crowther@adelaide.edu.au.
mesh_terms: D002547:Cerebral Palsy / Q000453:epidemiology* / Q000517:prevention & control; D019317:Evidence-Based Medicine; D005260:Female; D005313:Fetal Death / Q000517:prevention & control; D006801:Humans; D007226:Infant Mortality; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000453:epidemiology* / Q000517:prevention & control; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D011247:Pregnancy; D011256:Pregnancy Outcome; D047928:Premature Birth / Q000517:prevention & control*; D011295:Prenatal Care; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
chemical_list: D018696:Neuroprotective Agents; D008278:Magnesium Sulfate